BioMed Updates: JNJ, DYAX, HEB, SNTS, PLX, PFE, CVM, GILD, ENDP, TEVA, AMGN

$JNJ / Johnson + Johnson New FDA Filing for Tapentadol ER (pain drug) / IR forumation already approved (Nucynta)

$DYAX / Dyax Corp. Up Big AH / Receives FDA Approval for Kalbitor (ecallantide) for acute attacks HAE

$HEB / Hemispherx Tanks AH / FDA Complete Response Letter for Ampligen

$SNTS / Santarus Up Big AH / FDA Approval for Zegerid OTC

$PLX $PFE $GENZ $SHPGY / Protalix / trading lower after Pfizer pact (but no buyout) for Gaucher disease drug

$CVM / Cel-Sci / Retains CRO for pending Phase 3 pivotal trial of experimental cancer vaccine Multikine

$SNTS / Santarus / Dual Pending FDA Decisions for OTC Zegerid (9-Dec), Zegerid tablet reformulation (4-Dec)

$GILD / Gilead Sciences FDA Panel Review 10-Dec / aztreonam inhalation anti-infective for cystic fibrosis patients

$ENDP / Expected FDA Decision 2-Dec / Nebido (long-lasting testosterone injection)

$TEVA $AMGN Teva FDA Filing XM02 (G-CSF) Bio-Generic Amgen's Neupogen

Disclosure: No positions